{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "glucose (dextrose)",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "• Only for intravenous infusion. ( 2.1 ) • Infusion rate depends on the age, weight, clinical, and metabolic conditions of the patient and concomitant therapy. See full prescribing information for more information on preparation, administration, and dosing considerations. ( 2.1 , 2.2 , 2.3 ) 2.1 Important Administration Instructions Dextrose Injection (5%) is intended for intravenous use.",
        "source": "US FDA label for dextrose (Dextrose), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Dextrose Injection (5%) is indicated in pediatric patients as a source of water and calories, and may also be used as a diluent for reconstitution of a powder or liquid drug product. Neonates, especially preterm neonates with low birth weight, are at increased risk of developing hypo- or hyperglycemia.",
        "source": "US FDA label for dextrose (Dextrose), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      },
      {
        "text": "• Only for intravenous infusion. ( 2.1 ) • Infusion rate depends on the age, weight, clinical, and metabolic conditions of the patient and concomitant therapy. See full prescribing information for more information on preparation, administration, and dosing considerations. ( 2.1 , 2.2 , 2.3 ) 2.1 Important Administration Instructions Dextrose Injection (5%) is intended for intravenous use.",
        "source": "US FDA label for dextrose (Dextrose), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "Patients with underlying CNS disease and renal impairment who receive dextrose infusions may be at greater risk of developing hyperosmolar hyperglycemic state.",
        "source": "US FDA label for dextrose (Dextrose), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for dextrose (Dextrose), retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Dextrose Injection (5%) has been used for decades during labor and delivery.",
        "source": "US FDA label for dextrose (Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      },
      {
        "text": "Although there are a few case reports that describe adverse effects of dextrose use in other stages of pregnancy, exposure during pregnancy in general is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes.",
        "source": "US FDA label for dextrose (Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      },
      {
        "text": "Animal reproduction studies have not been conducted with dextrose.",
        "source": "US FDA label for dextrose (Dextrose), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary Dextrose Injection (5%) has been used for decades and is not expected to cause harm to a breastfed infant.",
        "source": "US FDA label for dextrose (Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      },
      {
        "text": "There are no data on the effects of Dextrose Injection (5%) on levels of glucose in human milk, on the breastfed infant, or on milk production.",
        "source": "US FDA label for dextrose (Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      },
      {
        "text": "The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Dextrose Injection (5%) and any potential adverse effects on the breastfed infant from Dextrose Injection (5%) or from the underlying maternal condition.",
        "source": "US FDA label for dextrose (Dextrose), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/glucose-dextrose.json",
        "verbatim": true
      }
    ]
  }
}